Circulation 122,210 • Volume 33, No. 1 • June 2018   Issue PDF

Systemic Lidocaine: An Effective and Safe Modality for Postoperative Pain Management and Early Recovery

Brent Earls, MD; Lisa Bellil, MD

Since its development in 1943, lidocaine has been a versatile medication in the armament of the anesthesia professional. Originally used as an anti-arrhythmic drug, it wasn’t long before its impact on pain was discovered.1 The earliest articles published showing pain reduction came out in the 1960s. Possibly due to the current opioid epidemic or perhaps because of the adoption of early recovery protocols and the concept of multimodal surgical care, lidocaine for analgesia has seen a re-emergence. From use in chronic pain syndromes to open abdominal surgery, lidocaine infusions have been incorporated and found to have positive results with a well-tolerated side effect profile. The antinociceptive properties of systemically administered lidocaine have repeatedly been shown in various experimental and clinical pain conditions.2-5 Some literature suggests that systemic administration of lidocaine may confer anti-metastatic benefits in some cancer patients.6 Studies have shown lidocaine to have a glycine-like action in the central nervous system at plasma levels far below what is required to prevent nerve impulse generation. The role of lidocaine in chronic inflammatory conditions is a much more recent area of research. Changes in expression of sodium-channel isoforms are involved, and lidocaine is believed to have its effect at these sites in the dorsal root ganglion.7 Additionally, lidocaine has been shown to modulate N-methyl-D-aspartate (NMDA) receptors, which could contribute to the prevention of chronic pain states.8,9 The therapeutic index of lidocaine has been investigated by several researchers and found to have optimum effects at 2–10 μg/mL2 and a total duration of 24–48 hours from the start of the infusion. Achieving and maintaining this level can be dependent on patient co-morbidities, age, and other factors that should be considered on a patient-by-patient basis.10

Lidocaine infusions have influenced numerous clinical outcomes investigated by researchers. Terkawi et al. conducted a trial including 216 patients and found lidocaine infusion to be equal with respect to pain scores to epidural analgesia in adults undergoing abdominal or pelvic surgery. They also found lower incidence of postoperative nausea and vomiting, pruritus, and urinary retention. However, the intravenous lidocaine group, receiving 1 mg/kg per hour for up to 96 hours postoperatively did have higher systemic opioid consumption when compared to the epidural analgesia group, who received a combination of 0.125% bupivicaine and 10 micrograms per milliliter of hydromorphone through the epidural.11 It comes as no surprise that thoracic and lumbar epidural analgesia does provide better pain relief at late time points, although studies are showing intravenous (IV) lidocaine to be a great alternative in patients who refuse neuraxial methods or have contraindications and can provide great analgesia up to two days after surgery.11-13

When administering a lidocaine infusion, it is important to discuss this plan with the surgical team prior to administering the infusion as well as to check for any contraindications in each patient (Table 1). Fortunately, lidocaine has a long-proven track record for safety as an IV medication and has been very well tolerated in the trials investigating the efficacy of this method.12,14,15

In 2015, a Cochrane review, which included 45 trials, was published comparing the effect of continuous perioperative lidocaine infusion either with placebo, or no treatment, or with epidural analgesia in adults under general anesthesia. The epidurals contained various solutions of dilute local anesthetics with or without low-dose opioids. The results suggested that the lidocaine infusion group had a reduction in postoperative pain at early and intermediate time points, expedited gastrointestinal recovery time, reduced postoperative nausea/vomiting and opioid usage as well as a reduction in hospital length of stay.16 There was limited data on adverse effects in the studies with the lidocaine intervention. However, most reported events were limited to light-headedness, tinnitus, or headache. There were no serious adverse events reported from these trials or poor surgical outcomes related to the lidocaine infusion reported in the treatment arm of the trials reviewed. Despite the more than 40 trials included in the review, more high-quality evidence is needed to delineate the clinical effect that can be expected with this modality. The Cochrane review concluded that there was low to moderate evidence. The authors also noted a scarcity of studies evaluating optimal dose, adverse effects, and timing, and further research is likely to have an important impact on the confidence in the estimate of effect.16

Rimback et al. compared systemic lidocaine (3 mg/min) versus normal saline placebo in 30 patients undergoing elective cholecystectomy in the early 1990s. They found reduced need for opioids, earlier return of bowel function, and shorter hospital stays. This group proposed a mechanism of less peritoneal irritation thus reducing inhibitory gastrointestinal reflexes.14 Several randomized, placebo-controlled clinical trials have demonstrated that IV lidocaine administration similarly reduces the duration of postoperative ileus and need for narcotic pain control, thus accelerating hospital discharge.12,14,15,17 In this early study, Rimbäck et al. implied that lidocaine infusions might reduce inflammation by blunting the sympathetic response and the associated inflammatory cascade.

Herroeder et al. performed a double-blind, randomized, controlled study in 60 patients undergoing colorectal surgery. Their results suggested that with systemic lidocaine (1.5 mg/kg bolus followed by a 2 mg/min infusion), patients were afforded shorter hospital stays and earlier return of bowel function. They were also able to show a measured reduction of a variety of inflammatory cytokines in the systemic lidocaine group.15 This study was able to showcase not only the central analgesic properties of local anesthetics but also the anti-inflammatory properties. This significant reduction in inflammatory mediators has implications in not only return of bowel function and postoperative ileus but also thrombosis, postoperative myocardial infarction, and sepsis.18

At Medstar Georgetown University Hospital, we have eagerly adopted IV lidocaine infusions as part of a balanced anesthetic plan. Several surgeons regularly incorporate IV lidocaine infusions into their perioperative treatment protocols. It is used as a fundamental component of our early recovery protocol in combination with acetaminophen, gabapentin, and celecoxib. This protocol is incorporated into most patients’ care undergoing colorectal surgery19 or, cholecystectomy; however, it has been used successfully in select patients not undergoing abdominal surgery. Patients are evaluated on an individual basis for candidacy of each medication. A thorough history and physical exam are performed to rule out contraindications to lidocaine (Table 1).

Table 1: Contraindications for Lidocaine Infusion26

Sensitivity or allergy to lidocaine
Significant heart disease (i.e., 2nd or 3rd degree heart block, Exception: Patients with a pacemaker)
Severe cardiac failure (Ejection fraction < 20%)
History of Adams-Stokes, Wolff-Parkinson-White Syndrome or active dysrhythmia
Concurrent treatment with Class I antiarrhythmics or amiodarone use < 3 months
Severe hepatic impairment (bilirubin > 1.46 mg/dl)
Severe renal impairment (< 30mL/min/1.73 m2 or ESRD)
History of uncontrolled seizure
Acute porphyria

During induction, the systemic administration is started with a one-time bolus of 1–1.5 milligrams per kilogram ideal body weight (IBW) after which time an infusion is initiated at 2 milligrams per kilogram per hour (IBW). This rate is continued for the first four hours and then reduced to 1 milligram per kilogram per hour for the remainder of the infusion period. Reducing the infusion rate after the first four hours is an effective and simple method to avoid toxic levels of lidocaine, but maintain a therapeutic concentration for pain control.20 Biotransformation of lidocaine yields metabolites monoethylglycinexlidide (MEGX) and glycine xylidide (GX). The systemic actions of these metabolites are similar to, but less potent than, lidocaine itself and are most pronounced when combined with concomitant administration with lidocaine. Pharmacokinetics of these metabolites can be diminished in individuals with liver cirrhosis21 and has even been developed as a more sensitive index than the Pugh score for liver dysfunction.22

After the patients are brought to the recovery room, our acute pain service takes over the management of the lidocaine infusion. This is an important step in maintaining safety during the infusion period to have early recognition of local anesthetic toxicity. Our staff will monitor patients at least every four hours for lightheadedness or dizziness, visual and auditory disturbances, or metallic taste and are available at all times for any concerns. Unfortunately, our clinical laboratory processes serum lidocaine as a send-out laboratory value, and, therefore, it can take up to three days to obtain a result, which limits its use in clinical practice. Therefore, if our staff recognizes or has suspicion of early signs of toxicity, the infusion is discontinued and the patient is moved to an intermediate care unit for continuous telemetry. Our protocol utilizes the Checklist for Local Anesthetic Systemic Toxicity (LAST) published by the American Society of Regional Anesthesia and Pain Medicine.23 As an additional precaution, the pharmacy will stock 20% IV fat emulsion in the automated medication dispensing system of floors where patients are receiving the infusion for quick access in case of emergency. Because lidocaine levels would not be processed in a clinically useful timeframe, it is important for us to recognize dangerous clinical signs and initiate treatment early. These signs include hypotension, seizure, loss of consciousness, and very late signs can include respiratory arrest and cardiac arrhythmia or arrest.24 If these signs are witnessed or suspected, the acute pain service attending physician is immediately notified and will determine the need for lipid emulsion. To date, we have not had any severe complications using our lidocaine infusion protocol since its implementation in the fall of 2017. Trials published using infusion rates for pain control document very few minor symptoms, which are self-limiting. Patients have noted symptoms including light-headedness, dizziness, tinnitus, or metallic taste in their mouth that resolve soon after discontinuation of the infusion. At this time, we recommend patients be monitored on the floor with continuous pulse oximetry without the need for routine telemetry. The lidocaine infusion is continued for 24 to 48 hours from initiation, as this is in line with the optimal clinical effect reported in most published trials we have investigated.11-15,17,18,25 Our acute pain service will continue to follow up for an additional day to provide an extra layer of patient safety and continue to assist with pain management as needed.

Dr. Earls is an R2 (PGY-2) anesthesiology resident at Medstar Georgetown University Hospital.

Dr. Bellil is Director of Obstetric Anesthesia, former Director of Acute Pain Service and Assistant Professor in the Department of Anesthesiology at Medstar Georgetown University Hospital.

Neither of the authors have any disclosures relevant to this article.

Special acknowledgment to Dr. David Dickerson, the Director of the Acute Pain Service and Assistant Professor in the Department of Anesthesia & Critical Care at the University of Chicago for serving as guest editor.

The information provided is for safety-related educational purposes only and does not constitute medical or legal advice. Individual or group responses are only commentary, provided for purposes of education or discussion, and are neither statements of advice nor the opinions of APSF. It is not the intention of APSF to provide specific medical or legal advice or to endorse any specific views or recommendations in response to the inquiries posted. In no event shall APSF be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the reliance on any such information.


  1. Bartlett EE, Hutserani O. Xylocaine for the relief of postoperative pain. Anesth Analg 1961;40:296–304.
  2. Tanelian DL, MacIver MB. Analgesic concentrations of lidocaine suppress tonic A-delta and C fiber discharges produced by acute injury. Anesthesiology 1991;74:934-936.
  3. Woolf CJ, Wiesenfeld-Hallin Z. The systemic administration of local anaesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord. Pain 1985;23:361–374.
  4. Basbaum AI. Distribution of glycine receptor immunoreactivity in the spinal cord of the rat: cytochemical evidence for a differential glycinergic control of lamina I and V nociceptive neurons. J Comp Neurol 1988;278:330–336.
  5. Abram SE, Yaksh TL. Systemic lidocaine blocks nerve injury-induced hyperalgesia and nociceptor-driven spinal sensitization in the rat. Anesthesiology 1994;80:383–391.
  6. Chamaraux-Tran TN, Piegeler T. The amide local anesthetic lidocaine in cancer surgery—potential antimetastatic effects and preservation of immune cell function? A Narrative Review. Front Med (Lausanne). 2017;4:235.
  7. Amir R, Argoff CE, Bennett GJ, et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 2006;7(5 Suppl 3):S1–29.
  8. Muth-Selbach U, Hermanns H, Stegmann JU, et al. Antinociceptive effects of systemic lidocaine: involvement of the spinal glycinergic system. Eur J Pharmacol 2009;613:68–73.
  9. Ahmadi S, Muth-Selbach U, Lauterbach A, et al. Facilitation of spinal NMDA receptor currents by spillover of synaptically released glycine. Science 2003;300: 2094–2097.
  10. Daykin H. The efficacy and safety of intravenous lidocaine for analgesia in the older adult: a literature review. Br J Pain 2017;11:23–31.
  11. Terkawi AS, Tsang S, Kazemi A, et al. A clinical comparison of intravenous and epidural local anesthetic for major abdominal surgery. Reg Anesth Pain Med 2016;41:28–36.
  12. Staikou C, Avramidou A, Ayiomamitis GD, et al. Effects of intravenous versus epidural lidocaine infusion on pain intensity and bowel function after major large bowel surgery: a double-blind randomized controlled trial. J Gastrointest Surg 2014;18:2155–2162.
  13. Wongyingsinn M, Baldini G, Charlebois P, et al. Intravenous lidocaine versus thoracic epidural analgesia: a randomized controlled trial in patients undergoing laparoscopic colorectal surgery using an enhanced recovery program. Reg Anesth Pain Med 2011;36:241–248.
  14. Rimback G, Cassuto J, Tollesson PO. Treatment of postoperative paralytic ileus by intravenous lidocaine infusion. Anesth Analg 1990;70:414–419.
  15. Herroeder S, Pecher S, Schonherr ME, et al. Systemic lidocaine shortens length of hospital stay after colorectal surgery: a double-blinded, randomized, placebo-controlled trial. Ann Surg 2007;246:192–200.
  16. Kranke P, Jokinen J, Pace NL, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery. Cochrane Database Syst Rev2015:CD009642.
  17. Groudine SB, Fisher HA, Kaufman RP, Jr., et al. Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy. Anesth Analg 1998;86:235–239.
  18. Rinder C, Fitch J. Amplification of the inflammatory response: adhesion molecules associated with platelet/white cell responses. J Cardiovasc Pharmacol 1996;27 Suppl 1:S6–12.
  19. Kaba A, Laurent SR, Detroz BJ, et al. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. Anesthesiology 2007;106:11–18; discussion 15–16.
  20. Wong BY, Hurwitz A. Simple method for maintaining serum lidocaine levels in the therapeutic range. Arch Intern Med 1985;145:1588–1591.
  21. Thomson AH, Elliott HL, Kelman AW, et al. The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. J Pharmacokinet Biopharm 1987;15:101–115.
  22. Huang YS, Lee SD, Deng JF, et al. Measuring lidocaine metabolite—monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993;19:140–147.
  23. Rubin DS, Matsumoto MM, Weinberg G, et al. Local anesthetic systemic toxicity in total joint arthroplasty: incidence and risk factors in the United States from the National Inpatient Sample 1998-2013. Reg Anesth Pain Med 2018;43:131–137.
  24. Di Gregorio G, Neal JM, Rosenquist RW, et al. Clinical presentation of local anesthetic systemic toxicity: a review of published cases, 1979 to 2009. Reg Anesth Pain Med 2010;35:181–187.
  25. Dunn LK, Durieux ME. Perioperative use of intravenous lidocaine. Anesthesiology 2017; 126: 729–737.
  26. Eipe N, Gupta S, Penning J. Intravenous lidocaine for acute pain: an evidence-based clinical update. BJA Education 2016; 16: 292–298.